Home > Site map > Report overview

Antibody Partnering Agreements

Published: Nov. 1, 2012 - 1023 Pages

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in antibody dealmaking: 2.1. Introduction; 2.2. Antibody partnering over the years; 2.3. Bigpharma antibody dealmaking activity; 2.4. Bigpharma not active in antibody partnering; 2.5. Antibody partnering by deal type; 2.6. Antibody partnering by disease type; 2.7. Partnering by antibody type; 2.8. Average deal terms for antibody partnering
Chapter 3 – Leading antibody deals: 3.1. Introduction; 3.2. Top antibody deals by value
Chapter 4 – Bigpharma antibody deals: 4.1. Introduction; 4.2. How to use bigpharma antibody partnering deals; 4.3. Bigpharma antibody partnering company profiles
Chapter 5 – Antibody dealmaking directory: 5.1. Introduction; 5.2. By stage of development; 5.3. By deal type; 5.4. By therapy area; 5.6. By antibody technology type
Chapter 6 – Antibody partnering resource center: 6.1. Online antibody partnering; 6.2. Antibody partnering events; 6.3. Further reading on antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures: Figure 1: Therapeutic antibody definitions; Figure 2: Antibody partnering since 2007; Figure 3: Bigpharma – top 50 – antibody deals 2007 to 2012; Figure 4: Bigpharma antibody deal frequency – 2007 to 2012; Figure 5: Inactive bigpharma in antibody 2007-2012; Figure 6: Antibody partnering by deal type since 2007; Figure 7: Antibody partnering by disease type since 2007; Figure 8: Antibody partnering by oncology target since 2007; Figure 9: Antibody partnering by therapeutic antibody type since 2007; Figure 10: Antibody deals with a headline value; Figure 11: Antibody deal headline value distribution, US$million – discovery stage; Figure 12: Antibody deal headline value distribution, US$million – preclinical stage; Figure 13: Antibody deal headline value distribution, US$million – phase I stage; Figure 14: Antibody deal headline value distribution, US$million – phase II stage; Figure 15: Antibody deal headline value distribution, US$million – phase III stage; Figure 16: Antibody deal headline value distribution, US$million – regulatory stage; Figure 17: Antibody deal headline value distribution, US$million – marketed stage; Figure 18: Summary median headline value by stage of development, 2007-2012; Figure 19: Antibody deals with upfront payment values; Figure 20: Antibody deal upfront payment distribution, US$million – discovery stage; Figure 21: Antibody deal upfront payment distribution, US$million – preclinical stage; Figure 22: Antibody deal upfront payment distribution, US$million – phase I stage; Figure 23: Antibody deal upfront payment distribution, US$million – phase II stage; Figure 24: Antibody deal upfront payment distribution, US$million – phase III stage; Figure 25: Antibody deal upfront payment distribution, US$million – regulatory stage; Figure 26: Antibody deal upfront payment distribution, US$million – marketed stage; Figure 27: Summary median upfront payments by stage of development, 2007-2012; Figure 28: Antibody deals with milestone payments; Figure 29: Antibody deal milestone distribution, US$million – discovery stage; Figure 30: Antibody deal milestone distribution, US$million – preclinical stage; Figure 31: Antibody deal milestone distribution, US$million – phase I stage; Figure 32: Antibody deal milestone distribution, US$million – phase II stage; Figure 33: Antibody deal milestone distribution, US$million – phase III stage; Figure 34: Antibody deal milestone distribution, US$million – regulatory stage; Figure 35: Antibody deal milestone distribution, US$million – marketed stage; Figure 36: Antibody deals with royalty rates, %; Figure 37: Antibody deal royalty rate distribution, US$million – discovery stage; Figure 38: Antibody deal royalty rate distribution, US$million – preclinical stage; Figure 39: Antibody deal royalty rate distribution, US$million – phase I stage; Figure 40: Antibody deal royalty rate distribution, US$million – phase II stage; Figure 41: Antibody deal royalty rate distribution, US$million – phase III stage; Figure 42: Antibody deal royalty rate distribution, US$million – regulatory stage; Figure 43: Antibody deal royalty rate distribution, US$million – marketed stage; Figure 44: Summary median royalty rate by stage of development, 2007-2012; Figure 45: Top antibody deals by value since 2007; Figure 46: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Cardiovascular); Figure 47: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Central Nervous System); Figure 48: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Dermatology); Figure 49: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Gastrointestinal); Figure 50: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Genteic disorders); Figure 51: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Genitourinary); Figure 52: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Gynaecology); Figure 53: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Hematology); Figure 54: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Hospital care); Figure 55: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Immunology); Figure 56: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Infectives); Figure 57: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Metabolic); Figure 58: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Musculoskeletal); Figure 59: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Oncology); Figure 60: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Ophthalmics); Figure 61: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Pediatrics); Figure 62: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Psychiatry); Figure 63: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Public health); Figure 64: Recent deals (Jan 2007 to Sep 2012) - By therapy area (Respiratory); Figure 65: Online partnering resources; Figure 66: Forthcoming partnering events

Abstract

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb

Polyclonal Antibodies

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1500 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibody deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibody partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

Antibody Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

Antibody Partnering Terms and Agreements includes:

Trends in antibody dealmaking in the biopharma industry since 2007
Analysis of antibody deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibody deals
Access to over 1500 antibody contract documents
The leading antibody deals by value since 2007
Most active antibody dealmakers since 2007
The leading antibody partnering resources

In Antibody Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific antibody type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Antibody Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1500 antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Get full details about this report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Antibody Partnering Agreements

Table of Contents

Abstract

US: 800.298.5699

Int'l: +1.240.747.3093